OverviewSuggest Edit

bioMérieux is a biotechnology company that provides diagnostic solutions, including reagents, instruments, software, and services, which determine the source of disease and contamination. Its products are used for diagnosing infectious diseases, cancer screening, and cardiovascular emergencies monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products.

TypePublic
Founded1963
HQMarcy-l'Étoile, FR
Websitebiomerieux.com
Employee Ratings4.2
Overall CultureA

Latest Updates

Employees (est.) (Dec 2020)12,800(+7%)
Revenue (FY, 2016)€2.1 B(+8%)
Share Price (Oct 2021)€99.2
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at bioMerieux

Alexandre MeRieux

Alexandre MeRieux

Chairman and CEO
Jean-Marc Durano

Jean-Marc Durano

Corporate Vice President, Industrial Microbiology Unit
Thierry Bernard

Thierry Bernard

Corporate Vice President, Global Commercial Operations
Pierre Boulud

Pierre Boulud

Chief Operating Officer, Clinical Operations
FrancOis Lacoste

FrancOis Lacoste

Corporate Vice President, Immunoassay Unit
Guillaume Bouhours

Guillaume Bouhours

Executive Vice President, CFO, Purchasing, Information Systems
Show more

bioMerieux Office Locations

bioMerieux has offices in Marcy-l'Étoile, Bruz, Combourg, Craponne and in 58 other locations
Marcy-l'Étoile, FR (HQ)
376 Chemin de l'Orme
Bruz, FR
Rue Maryse Bastié CS17219
Combourg, FR
2 Rue du Moulin Madame
Craponne, FR
5 Rue des Aqueducs
Grenoble, FR
5 Rue des Berges
Ivry-sur-Seine, FR
All. Postillon
Show all (66)

bioMerieux Financials and Metrics

bioMerieux Revenue

Embed Graph
View revenue for all periods
bioMerieux's revenue was reported to be €2.1 b in FY, 2016 which is a 7.1% increase from the previous period.
EUR

Revenue (FY, 2016)

2.1b

Revenue growth (FY, 2015 - FY, 2016), %

7.1%

Gross profit (FY, 2016)

1.1b

Gross profit margin (FY, 2016), %

52.3%

Net income (FY, 2016)

179.2m

EBIT (FY, 2016)

282.5m

Market capitalization (15-Oct-2021)

11.7b

Closing stock price (15-Oct-2021)

99.2

Cash (31-Dec-2016)

178.6m

EV

12.0b
bioMerieux's current market capitalization is €11.7 b.
EURFY, 2014FY, 2015FY, 2016

Revenue

1.7b2.0b2.1b

Revenue growth, %

16%7%

Cost of goods sold

853.9m975.4m1.0b

Gross profit

844.5m989.2m1.1b
EURFY, 2014FY, 2015FY, 2016

Cash

119.7m147.1m178.6m

Accounts Receivable

449.3m445.1m465.8m

Inventories

299.2m355.8m404.4m

Current Assets

991.4m1.1b1.2b
EURFY, 2014FY, 2015FY, 2016

Net Income

135.5m110.3m179.2m

Cash From Operating Activities

298.3m310.0m335.6m

Purchases of PP&E

(158.1m)(208.2m)(233.0m)

Cash From Investing Activities

(502.7m)(208.0m)(257.2m)
EURFY, 2014

Debt/Equity

0.3 x

Debt/Assets

0.1 x

Financial Leverage

1.9 x
Show all financial metrics

bioMerieux Operating Metrics

FY, 2015FY, 2016

Countries

150

Facilities

19

Patents and Patent Applications

581529
Show all operating metrics

bioMerieux Online and Social Media Presence

Embed Graph

bioMerieux Company Culture

  • Overall Culture

    A

    76/100

  • CEO Rating

    A+

    79/100

  • Compensation

    A-

    78/100

Learn more on Comparably

bioMerieux News and Updates

Worldwide Companion Diagnostics Industry to 2026 - Featuring Agilent Technologies, BioMerieux and Myriad Genetics Among Others

Dublin, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The "Companion Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global companion diagnostics market exhibited strong growth during 2015-2020…

Worldwide PCR For Respiratory Infection Diagnostic Industry to 2028 - Players Include Abbott, Hologic and bioMerieux Among Others

Dublin, Sept. 03, 2021 (GLOBE NEWSWIRE) -- The "PCR For Respiratory Infection Diagnostic Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type, Multiplex PCR, Traditional PCR, Digital PCR, Reverse-Transcriptase,and Others, Product Type, Infection Type, End Users and Geography" repo…

Global Autoimmune Disease Diagnostics Market (2021 to 2026) - Featuring BD Biosciences, Biomerieux and Siemens Healthcare Among Others

Dublin, Aug. 24, 2021 (GLOBE NEWSWIRE) -- The "Autoimmune Disease Diagnostics: Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Life science firm bioMerieux, SAS partner to tackle antimicrobial resistance

bioMérieux Inc., a world leader in in vitro diagnostic solutions for infectious disease, has partnered with global analytics leader SAS to help combat antimicrobial resistance.

The expansion of our International Distribution Center at Saint-Vulbas (France) has officially started

A new 4,500-m2 building will increase the surface area by 50%! 🏢 It is part of a larger #project which aims to increase the site’s capacity and develop its agility, thanks to new IT tools and state-of-the-art automation, while preserving the environment and the well-being of the women and men who w…

In the fight against Antimicrobial Resistance, bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe

bioMérieux, a world leader in the field of in vitro diagnostics, and Specific Diagnostics, a company bringing unique in vitro diagnostic systems to clinical microbiology, announce that bioMérieux will distribute Specific Diagnostics’ newly introduced REVEAL Rapid AST system in Europe.
Show more

bioMerieux Frequently Asked Questions

  • When was bioMerieux founded?

    bioMerieux was founded in 1963.

  • Who are bioMerieux key executives?

    bioMerieux's key executives are Alexandre MeRieux, Jean-Marc Durano and Thierry Bernard.

  • How many employees does bioMerieux have?

    bioMerieux has 12,800 employees.

  • What is bioMerieux revenue?

    Latest bioMerieux annual revenue is €2.1 b.

  • What is bioMerieux revenue per employee?

    Latest bioMerieux revenue per employee is €164.3 k.

  • Who are bioMerieux competitors?

    Competitors of bioMerieux include Phitonex, Danaher and Qiagen.

  • Where is bioMerieux headquarters?

    bioMerieux headquarters is located at 376 Chemin de l'Orme, Marcy-l'Étoile.

  • Where are bioMerieux offices?

    bioMerieux has offices in Marcy-l'Étoile, Bruz, Combourg, Craponne and in 58 other locations.

  • How many offices does bioMerieux have?

    bioMerieux has 66 offices.